Cytomed Therapeutics says H1 2026 net loss narrows 20.1% to S$1.79 million
GDTC•Cytomed Therapeutics reported a net loss of S$1.79 million for the six months ended June 30, 2026, down 20.1%, while cash and bank balances fell to S$1.46 million.
1. Loss and cash balances
Management cited lower other expenses, led by reduced share-based consultancy costs, partly offset by higher investor relations spending. Other income fell to S$254,719, private blood banking revenue was S$157,289, and financing inflows included a S$699,600 director loan.
